Tricida Inc
Change company Symbol lookup
Select an option...
TCDAQ Tricida Inc
HROWL HARROW HEALTH 8 625 SNR NTS
MLTX MoonLake Immunotherapeutics
TRTN Triton International Ltd
PAYA Paya Holdings Inc
MA Mastercard Inc
MWRK MetaWorks Platforms Inc
NSRGY Nestle SA
MIN MFS? Intermediate Income Fund
MCO Moody's Corp
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Tricida, Inc. is a pharmaceutical company, which is focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101). TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. It is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The Company's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.

Closing Price
$0.0491
Day's Change
-0.0029 (-5.58%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0529
Day's Low
0.0427
Volume
(Light)
Volume:
5,327,152

10-day average volume:
23,112,362
5,327,152

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Palantir Technologies Inc. with Losses of $500,000 to Contact the Firm

8:34 am ET November 14, 2022 (Newsfile) Print

Los Angeles, California--(Newsfile Corp. - November 14, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Palantir Technologies Inc. ("Palantir" or "the Company") (NYSE: PLTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 16, 2021 and May 6, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before November 14, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Palantir's earnings per share ("EPS") results suffered due to the Company's investments in marketable securities. The Company overstated the growth and sustainability prospects of its government business. The Company suffered from a marked slowdown in revenue growth despite ongoing global conflicts. The Company was likely to miss consensus estimates of EPS for the first quarter of 2022. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Palantir, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

SOURCE:

The Schall Law Firm

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/144120

comtex tracking

COMTEX_418844189/2523/2022-11-14T08:34:20

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.